Literature DB >> 33219367

Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk.

Weiqiang Li1, Robert J Klein2.   

Abstract

BACKGROUND: Benign prostatic hyperplasia (BPH) is common noncancerous prostate enlargement, which is usually associated with lower urinary tract symptoms (LUTS) and can lead to complex urinary, bladder, or kidney diseases. The majority of elderly men will be affected by BPH as age increases.
METHODS: Here, we conducted a genome-wide association study (GWAS) of BPH using 1942 cases and 4730 controls from the Electronic Medical Records and Genomics network (eMERGE) as discovery cohort. We then used 5109 cases and 161,911 controls from UK Biobank as validation cohort.
RESULTS: This GWAS discovered 35 genome-wide significant variants (P < 5 × 10-8), located at 22 different loci in discovery cohort. We validated four significant variants located at four different loci in validation cohort: rs8027714 at 15q11.2, rs8136152 at 22q13.2, rs10192133 at 2q24.2, and rs1237696 at 11q22.1. rs1237696 is an intronic variant on chromosome 11 in the progesterone receptor (PGR) gene (P = 4.21 ×10-8, OR [95% CI] = 1.36 [1.22-1.52]). PGR is a known drug target for BPH as the PGR agonist gestonorone caproate has been used to treat BPH in multiple countries.
CONCLUSIONS: Our results suggest that genetic variants identified from BPH GWAS can identify pharmacologic targets for BPH treatment.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33219367     DOI: 10.1038/s41391-020-00303-2

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  43 in total

Review 1.  Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms.

Authors:  Aruna V Sarma; John T Wei
Journal:  N Engl J Med       Date:  2012-07-19       Impact factor: 91.245

2.  Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia.

Authors:  Sadao Suzuki; Elizabeth A Platz; Ichiro Kawachi; Walter C Willett; Edward Giovannucci
Journal:  Am J Clin Nutr       Date:  2002-04       Impact factor: 7.045

Review 3.  Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis.

Authors:  Mauro Gacci; Giovanni Corona; Linda Vignozzi; Matteo Salvi; Sergio Serni; Cosimo De Nunzio; Andrea Tubaro; Matthias Oelke; Marco Carini; Mario Maggi
Journal:  BJU Int       Date:  2014-08-16       Impact factor: 5.588

Review 4.  Prostatic fibrosis, lower urinary tract symptoms, and BPH.

Authors:  Jose A Rodriguez-Nieves; Jill A Macoska
Journal:  Nat Rev Urol       Date:  2013-07-16       Impact factor: 14.432

5.  Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels.

Authors:  R B Nadler; P A Humphrey; D S Smith; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

6.  Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Authors:  Andrew J Vickers; Angel M Cronin; Thomas Björk; Jonas Manjer; Peter M Nilsson; Anders Dahlin; Anders Bjartell; Peter T Scardino; David Ulmert; Hans Lilja
Journal:  BMJ       Date:  2010-09-14

Review 7.  Management of Benign Prostatic Hyperplasia.

Authors:  Eric H Kim; Jeffrey A Larson; Gerald L Andriole
Journal:  Annu Rev Med       Date:  2015-09-02       Impact factor: 13.739

8.  Is there a link between BPH and prostate cancer?

Authors:  R T M Chang; Roger Kirby; B J Challacombe
Journal:  Practitioner       Date:  2012-04

9.  The development of human benign prostatic hyperplasia with age.

Authors:  S J Berry; D S Coffey; P C Walsh; L L Ewing
Journal:  J Urol       Date:  1984-09       Impact factor: 7.450

10.  Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.

Authors:  Julius Gudmundsson; Jon K Sigurdsson; Lilja Stefansdottir; Bjarni A Agnarsson; Helgi J Isaksson; Olafur A Stefansson; Sigurjon A Gudjonsson; Daniel F Gudbjartsson; Gisli Masson; Michael L Frigge; Simon N Stacey; Patrick Sulem; Gisli H Halldorsson; Vinicius Tragante; Hilma Holm; Gudmundur I Eyjolfsson; Olof Sigurdardottir; Isleifur Olafsson; Thorvaldur Jonsson; Eirikur Jonsson; Rosa B Barkardottir; Rafn Hilmarsson; Folkert W Asselbergs; Gudmundur Geirsson; Unnur Thorsteinsdottir; Thorunn Rafnar; Gudmar Thorleifsson; Kari Stefansson
Journal:  Nat Commun       Date:  2018-11-08       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.